Why the study?
The association between RAAS blocker use and AKI in elderly STEMI patients was unknown, and data on the effect of inflammatory markers were limited.
Does RAAS blocker pretreatment affect acute kidney injury in elderly hypertensive STEMI patients?
Does RAAS blocker pretreatment affect acute kidney injury in elderly hypertensive STEMI patients?
In elderly hypertensive STEMI patients, RAAS blocker pretreatment was not associated with an increased risk of acute kidney injury, whereas baseline creatinine and C-reactive protein/albumin ratio were independent predictors.
May not support RAAS blocker discontinuation for AKI prevention in elderly hypertensive STEMI; leaves open prospective validation of creatinine and CRP/albumin predictors.
Studies reported conflicting results on the effect of renin-angiotensin-aldosterone system (RAAS) blocker use on acute kidney injury (AKI) in patients undergoing elective coronary angiography but association in elderly patients with ST-elevation myocardial infarction (STEMI) is not known. Also, there are limited data on the effect of inflammatory markers on AKI. We aimed to investigate the effects of RAAS blocker pretreatment and inflammatory markers on AKI in this population. A total of 471 patients were compared according to presence of RAAS blocker pretreatment at admission. Conventional and inverse probability weighed conditional logistic regression were used to determine independent predictors of AKI. Mean age of the study group was 75.4 ± 7.1 years and 29.1% of the patients were female. AKI was observed in 17.2% of the study population. Weighted conditional multivariable logistic regression analysis revealed that AKI was associated with baseline creatinine levels and C-reactive protein/albumin ratio (CAR) (OR 2.08, 95% CI = 1.13-3.82, p = .02 and OR 1.19, 95% CI = 1.01-1.41, p = .04, respectively). No significant association was found between RAAS blocker pretreatment and AKI. CAR and elevated baseline creatinine levels were independent predictors of AKI in this patient group.
No takes yet. Share an insight, caveat, or question.
Zeren et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: